The ADA Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human hepatic adenocarcinoma cell line SK-HEP-1. This product features targeted disruption of the ADA gene, which encodes adenosine deaminase, a key enzyme in purine metabolism responsible for the irreversible deamination of adenosine and 2′-deoxyadenosine to inosine and 2′-deoxyinosine, respectively. The polyclonal nature of the knockout population ensures representation of diverse gene-editing events, providing a robust loss-of-function model without clonal selection bias.
SK-HEP-1 cells were originally isolated from the ascitic fluid of a patient with liver adenocarcinoma and have been widely employed as a model system for hepatocellular carcinoma research. These cells exhibit epithelial morphology and retain characteristics relevant for studying hepatic tumor biology, including drug metabolism, signal transduction, and cell?Cmatrix interactions. Their use as an ADA knockout host enables investigation of adenosine metabolism specifically within a liver cancer context, offering insights into tumor-intrinsic purine handling and its consequences.
ADA functions as a key regulator of extracellular adenosine levels by catalyzing the conversion of adenosine to inosine, thereby reducing adenosine availability for adenosine receptor (A2AR and A2BR) activation. This activity is modulated by upstream signals from the T cell receptor and Notch pathways, and ADA physically interacts with CD26 (DPP4) and adenosine deaminase complexing protein-2. In the absence of ADA, accumulation of adenosine and deoxyadenosine leads to enhanced A2AR/A2BR signaling and elevated intracellular cAMP, which can impair lymphocyte development and function. Thus, ADA sits at the intersection of purine metabolism and immune signaling, with direct relevance to adenosine-mediated immunosuppression in the tumor microenvironment.
In the SK-HEP-1 hepatic adenocarcinoma background, loss of ADA disrupts the normal catabolism of adenosine, perturbing the balance between adenosine and inosine and potentially altering downstream cAMP-dependent pathways. This model enables researchers to dissect how adenosine metabolism influences liver cancer cell proliferation, survival, and response to adenosine receptor agonists or antagonists. Since adenosine is a known modulator of tumor immunity and angiogenesis, the ADA knockout cells provide a valuable tool for exploring metabolic crosstalk between cancer cells and their microenvironment, particularly in the context of adenosinergic signaling.
Typical applications include western blotting for ADA protein, RT-qPCR for ADA mRNA, and adenosine deaminase activity assays. The cells are suited for adenosine receptor signaling studies, cAMP measurement, and proliferation assays under adenosine treatment. They can model ADA deficiency in a liver cell context and be used for drug screening targeting purine metabolism. For additional information, assay protocols, or technical support, please contact Ascent Research.
